Glucose Meters in North Carolina

Laboratory Corporation of America Holdings (Labcorp) is a global leader in laboratory services headquartered in Burlington, North Carolina. Operating in approximately 100 countries with over 70,000 employees, Labcorp performs more than 700 million tests annually and generates $13.01 billion in revenue. The company provides comprehensive clinical diagnostics, drug development support, and specialized testing including oncology, rare diseases, and genomic sequencing. Labcorp's integrated platform connects diagnostics to biopharma development, supporting healthcare providers, researchers, and investigators. Key offerings include AI-powered diagnostic assistance tools, real-world data platforms for drug development, genetic testing services (including Invitae), nonclinical research, central laboratory services, and clinical trial support. The company serves patients, healthcare providers, health systems, managed care organizations, and biopharmaceutical companies. Over 75% of new drugs approved by the FDA have been supported by Labcorp's services.

Prodigy Diabetes Care, LLC is a manufacturer of blood glucose monitoring systems and diabetes management products. The company specializes in innovative glucose meters designed for home and clinical use, including talking meters (AFB/NFB award-winning), multilingual models (four-language support), and interchangeable test strip platforms compatible across multiple meter models. Prodigy's product line includes the PRODIGY AutoCode® and PRODIGY Pocket® meters. The company also develops companion software for data management, scheduling, target setting, reporting, graphing, and result tracking. Products are distributed through healthcare distributors to patients and healthcare providers. The company maintains a professionally trained customer care team providing technical support, warranty activation, and product troubleshooting. Prodigy's mission is to establish standards of excellence in blood glucose monitoring systems and encourage people with diabetes to live well with their condition. The company operates in the home diabetes monitoring segment, serving individuals requiring regular glucose monitoring.

UniStrip Technologies, LLC manufactures and distributes generic blood glucose test strips under the TruePoint and UNISTRIP brand names. The company specializes in glucose monitoring consumables designed as compatible alternatives to proprietary OneTouch test strips. TruePoint test strips utilize glucose oxidase technology and are compatible with multiple OneTouch meter models including Ultra, UltraMini, Ultra 2, and UltraSmart. The company markets its products as providing safer and more accurate results compared to branded alternatives. UniStrip serves the home diabetes management and personal medical device market, targeting patients and healthcare systems seeking cost-effective glucose monitoring supplies. Distribution channels include retail and direct-to-consumer purchase options. The company positions itself as a supplier of generic diabetes care consumables for the homecare market.

Rasimo Systems is an FDA-listed integrated health technology company specializing in AI-driven digital therapeutics and remote patient monitoring solutions. The company develops the SureMediks® platform, a comprehensive AI-powered digital health ecosystem designed to manage metabolic risk factors including obesity, diabetes, cardiovascular disease, and MASLD. SureMediks integrates connected medical devices (blood pressure monitors, smart scales, glucose meters, ECG wearables, oximeters, CGM systems, and smart rings) with proprietary "Realistic Intelligence" AI to deliver real-time patient monitoring, personalized treatment pathways, lifestyle interventions, and clinical decision support. The platform connects seamlessly to existing EMR systems via standard APIs and includes customizable dashboards for healthcare providers. Rasimo manufactures FDA-compliant medical devices and offers end-to-end solutions including custom device design, medical software development, EMR integration, and HIPAA-compliant telehealth systems. The company also produces AI-enabled hearing aids (BTE, RIC, ITE styles) and wellness platforms (SureFiz Pro). Serves healthcare providers, pharmaceutical companies, insurers, fitness professionals, and enterprise wellness programs.

Precision Diabetes, Inc. is an emerging leader in precision medicine for diabetes, headquartered in Raleigh, North Carolina (Research Triangle Park). The company develops and markets novel diabetes biomarkers and diagnostic tests that span diabetes risk assessment through complication detection. Primary product is GlycoMark, a proprietary diabetes biomarker test for which Precision Diabetes holds exclusive distribution rights across the United States, Europe, Australia, Asia-Pacific, Middle East, and Mexico. GlycoMark is validated as a prediabetes biomarker and novel indicator of SGLT-2 inhibitor adherence; recent clinical data suggests utility in COVID-19 severity assessment. The company also partners with Patia Europe to distribute DIABETESpredict (type 2 diabetes genetic testing) and Matergen (gestational diabetes genetic testing) in the U.S. market. Precision Diabetes maintains a strategic partnership with DxGen Corp. to commercialize a point-of-care diabetes testing analyzer. The portfolio addresses both clinical laboratory and point-of-care testing modalities, serving endocrinology, primary care, and hospital laboratory markets. Company demonstrates active clinical research engagement, with publications and presentations at major conferences including the American Diabetes Association.